Driving production in biologics development with automation

Drug development technology has evolved rapidly in recent years, and with the industry, advancement comes an increased capability of producing high-quality targeted large molecule drugs such as biologics and biosimilars.

Since most biologics are large molecules, they may prove challenging to develop and manufacture on the large scale. However, the adoption of automation in the lab setting can set the stage for a pilot phase to drive optimisation and efficiency into a new era of drug development and manufacturing. Here, Perkin Elmer highlights the ways automation is helping to improve biologics production.

Click here to listen

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free